Skip to main content

Table 1 Biodistribution data of [18F]FPyPEGCBT-c(RGDfK) in nude mice bearing U-87 MG or SKOV-3 subcutaneous tumoursa

From: Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis

Organ

30 min

60 min

60 min blocking

120 min

Blood

8.08 ± 1.72

3.76 ± 1.08

6.14 ± 1.39

2.96 ± 1.83

Muscle

1.32 ± 0.32

0.64 ± 0.14

1.12 ± 0.38

0.77 ± 0.16

Bone

1.34 ± 0.34

0.88 ± 0.25

0.91 ± 0.35

1.02 ± 0.30

Heart

3.92 ± 0.78

2.01 ± 0.43

2.99 ± 0.82

1.45 ± 0.45

Lung

6.10 ± 1.39

2.77 ± 0.55

4.83 ± 0.82

2.93 ± 0.82

Pancreas

1.29 ± 0.40

0.71 ± 0.13

1.09 ± 0.39

0.63 ± 0.12

Spleen

1.87 ± 0.25

0.96 ± 0.21

1.28 ± 0.46

1.03 ± 0.34

Adrenals

5.37 ± 0.94

3.47 ± 0.53

1.13 ± 0.51

2.71 ± 0.29

Kidney

6.56 ± 0.85

3.61 ± 0.49

5.59 ± 1.17

2.77 ± 0.77

Liver

8.82 ± 1.25

4.43 ± 1.31

5.19 ± 1.19

5.04 ± 2.07

Stomach

1.48 ± 1.00

1.26 ± 0.58

1.45 ± 1.21

0.60 ± 0.24

Duodenum

30.31 ± 8.17

16.56 ± 8.68

22.38 ± 10.82

31.39 ± 22.29

Jejunum

55.07 ± 47.42

69.80 ± 20.76

45.88 ± 9.85

9.58 ± 7.36

Ileum

2.78 ± 1.23

13.31 ± 7.14

8.45 ± 10.81

8.89 ± 8.33

U-87 MG Tumour

3.56 ± 0.78

2.89 ± 0.53

0.89 ± 0.31

2.80 ± 0.70

SKOV-3 Tumour

3.47 ± 0.93

2.42 ± 0.40

0.73 ± 0.30

2.12 ± 0.56

Tumour-to-non-tumour ratios

 U87-MG to Blood

0.44 ± 0.13

0.77 ± 0.06

0.14 ± 0.04

0.83 ± 0.78

 U87-MG to Muscle

2.45 ± 0.53

4.51 ± 0.58

0.90 ± 0.30

3.64 ± 1.55

 SKOV-3 to Blood

0.43 ± 0.17

0.64 ± 0.18

0.12 ± 0.06

0.63 ± 0.51

 SKOV-3 to Muscle

2.39 ± 1.22

3.78 ± 1.08

0.74 ± 0.45

2.76 ± 0.89

  1. aResults are expressed as mean %ID/g at indicated uptake times ± SD (n ≥ 7)